Hikma is lined up to copy 4 of the blockbuster drugs on this tracker, which earned $15.7B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Hikma's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Stelara Starjemza |
Johnson & Johnson | Biosimilar | 2025 | FDA-approved biosimilar | $6.1B |
| Prolia Enoby |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $4.4B |
| Xgeva Xtrenbo |
Amgen | Biosimilar | 2025 | FDA-approved biosimilar | $2.1B |
| Jakafi | Incyte | Generic | 2028 | Settled, terms confidential | $3.1B |
Company facts: Hikma. Each drug page lists sources for these entries. Brand sales show the size of the market, not Hikma's share of it.